Entry ID,Ligand,Value,Symbol,Type,Unit,PDB ID,Title,Structure Title,Stucture Keywords,Gene Name,EC Number,Annotation Identifier,Entity ID,Entry Id (Polymer Entity Identifiers),Target Protein,Accession Code(s),Database Name,Ligand Formula,Ligand MW,Ligand ID,Ligand Name,Ligand SMILES,Entity ID
7PSC,,,,,,7PSC,Crystal structure of the disease-causing I358T mutant of the human dihydrolipoamide dehydrogenase,Crystal structure of the disease-causing I358T mutant of the human dihydrolipoamide dehydrogenase,OXIDOREDUCTASE,"DLD, GCSL, LAD, PHE3",1.8.1.4,"GO:0043159, GO:0005947, GO:0005759, GO:0005967, GO:0005739, GO:0031514, GO:0005634, GO:0045252, GO:0045254, GO:0004148, GO:0050660, GO:0006086, GO:0009083, GO:0045454, GO:0007369, GO:0106077, GO:0006120, GO:0006508, GO:0042391, GO:0048240, IPR036188, IPR023753, IPR016156, IPR006258, IPR001100, IPR004099, IPR012999, P09622",1,7PSC,Mutant,P09622,UniProt,C27 H33 N9 O15 P2,785.55,FAD,FLAVIN-ADENINE DINUCLEOTIDE,Cc1cc2c(cc1C)N(C3=NC(=O)NC(=O)C3=N2)CC(C(C(COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)n5cnc6c5ncnc6N)O)O)O)O)O,2
7UGE,,,,,,7UGE,Structural basis of CBP and EP300 interaction with kinase inhibitors,Bromodomain of CBP liganded with BMS-536924,TRANSCRIPTION,CREBBP,2.3.1.48,"GO:0016604, GO:0005654, GO:0004402, GO:0003712, GO:0016573, GO:0045944, IPR001487, IPR036427, IPR018359, IPR031162, IPR013178, IPR003101, IPR036529, IPR010303, IPR038547, IPR013083",1,7UGE,wildtype,I3L466,UniProt,C25 H26 Cl N5 O3,479.959,N6I,(3M)-4-{[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-3-[4-methyl-6-(morpholin-4-yl)-1H-benzimidazol-2-yl]pyridin-2(1H)-one,Cc1cc(cc2c1nc([nH]2)C3=C(C=CNC3=O)NCC(c4cccc(c4)Cl)O)N5CCOCC5,2
7UGL,,,,,,7UGL,Structural basis of CBP and EP300 interaction with kinase inhibitors,Bromodomain of CBP liganded with BMS-536924 and SGC-CBP30,TRANSCRIPTION,CREBBP,2.3.1.48,"GO:0016604, GO:0005654, GO:0004402, GO:0003712, GO:0016573, GO:0045944, IPR001487, IPR036427, IPR018359, IPR031162, IPR013178, IPR003101, IPR036529, IPR010303, IPR038547, IPR013083",1,7UGL,wildtype,I3L466,UniProt,C25 H26 Cl N5 O3,479.959,N6I,(3M)-4-{[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-3-[4-methyl-6-(morpholin-4-yl)-1H-benzimidazol-2-yl]pyridin-2(1H)-one,Cc1cc(cc2c1nc([nH]2)C3=C(C=CNC3=O)NCC(c4cccc(c4)Cl)O)N5CCOCC5,2
7UGL,,,,,,7UGL,Structural basis of CBP and EP300 interaction with kinase inhibitors,Bromodomain of CBP liganded with BMS-536924 and SGC-CBP30,TRANSCRIPTION,CREBBP,2.3.1.48,"GO:0016604, GO:0005654, GO:0004402, GO:0003712, GO:0016573, GO:0045944, IPR001487, IPR036427, IPR018359, IPR031162, IPR013178, IPR003101, IPR036529, IPR010303, IPR038547, IPR013083",1,7UGL,wildtype,I3L466,UniProt,C28 H33 Cl N4 O3,509.04,2LO,"2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-benzimidazole",Cc1c(c(on1)C)c2ccc3c(c2)nc(n3CC(C)N4CCOCC4)CCc5ccc(c(c5)Cl)OC,3
7UIA,,,,,,7UIA,Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2.,Crystal structure of BoNT/E receptor binding domain in complex with SV2 and VHH,TOXIN,,,"GO:0005576, GO:0008237, GO:0046929, GO:0006508, IPR013320, IPR011065, IPR013104, IPR012928",3,7UIA,wildtype,A5H0J8,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7UOW,,,,,,7UOW,SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 034_32,SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 034_32,VIRAL PROTEIN,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,7UOW,wildtype,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7US2,,,,,,7US2,"PARL-cleaved Skd3 (human ClpB) E455Q Nucleotide Binding Domain hexamer bound to ATPgammaS, open conformation","PARL-cleaved Skd3 (human ClpB) E455Q Nucleotide Binding Domain hexamer bound to ATPgammaS, open conformation",CHAPERONE,"CLPB, HSP78, SKD3",3.6.1,"GO:0005737, GO:0005758, GO:0005739, GO:0005524, GO:0016887, GO:0140374, GO:0034605, GO:0039529, IPR003593, IPR002110, IPR036770, IPR003959, IPR019489, IPR001270, IPR027417, Q9H078",1,7US2,wildtype,Q9H078,UniProt,C10 H16 N5 O12 P3 S,523.247,AGS,PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=S)(O)O)O)O)N,3
7X0S,,,,,,7X0S,Pathway and mechanism of tubulin folding mediated by TRiC/CCT conjugated with its ATPase cycle revealed by cryo-EM,Human TRiC-tubulin-S3,STRUCTURAL PROTEIN,"CCT6A, CCT6, CCTZ",,"GO:0005832, GO:0005737, GO:0005829, GO:0070062, GO:0005874, GO:0005524, GO:0016887, GO:0140662, GO:0044183, GO:0003723, GO:0051082, GO:0071987, GO:0061077, GO:1904851, GO:1904871, GO:1904874, GO:0032212, GO:0006457, GO:0050821, IPR012722, IPR017998, IPR002194, IPR002423, IPR027409, IPR027413, IPR027410, P40227",1,7X0S,Mutant,P40227,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,10
7X0V,,,,,,7X0V,Pathway and mechanism of tubulin folding mediated by TRiC/CCT conjugated with its ATPase cycle revealed by cryo-EM,cryo-EM structure of human TRiC-ADP-AlFx,STRUCTURAL PROTEIN,"CCT7, CCTH, NIP7-1",,"GO:0044297, GO:0005832, GO:0005737, GO:0005829, GO:0070062, GO:0005874, GO:0005524, GO:0016887, GO:0140662, GO:0044183, GO:0051082, GO:0007339, GO:0061077, GO:1904851, GO:1904871, GO:1904874, GO:0032212, GO:0006457, GO:0050821, GO:1901998, IPR012720, IPR017998, IPR002194, IPR002423, IPR027409, IPR027413, IPR027410, Q99832",3,7X0V,Mutant,Q99832,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,9
7XJ6,,,,,,7XJ6,SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab and 58G6 Fab in the class 1 conformation,SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab and 58G6 Fab in the class 1 conformation,VIRAL PROTEIN/IMMUNE SYSTEM,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,7XJ6,Mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,7
7XJ8,,,,,,7XJ8,SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab and 58G6 Fab in the class 2 conformation,SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab and 58G6 Fab in the class 2 conformation,VIRAL PROTEIN/IMMUNE SYSTEM,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,7XJ8,Mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,7
7XK9,,,,,,7XK9,Structure of human beta2 adrenergic receptor bound to constrained isoproterenol,Structure of human beta2 adrenergic receptor bound to constrained isoproterenol,MEMBRANE PROTEIN,E,3.2.1.17,"GO:0016324, GO:0030669, GO:0005769, GO:0005768, GO:0010008, GO:0005794, GO:0005764, GO:0016020, GO:0005634, GO:0005886, GO:0043235, GO:0008179, GO:0001540, GO:0004941, GO:0004930, GO:0042802, GO:0051380, GO:0015459, GO:0042803, GO:0044877, GO:0007190, GO:0007171, GO:0071880, GO:0007188, GO:0071875, GO:0045453, GO:0050873, GO:0007166, GO:1904646, GO:0002032, GO:0002024, GO:0008333, GO:0031649, GO:0040015, GO:0045986, GO:0002025, GO:2000969, GO:1901098, GO:0030501, GO:2000481, GO:0120162, GO:1904504, GO:0043410, GO:0061885, GO:0010739, GO:0071902, GO:0045944, GO:0006898, GO:0002028, GO:0009409, GO:1990911, GO:0006939, GO:0006366, IPR002233, IPR000332, IPR000276, IPR017452, GO:0030430, GO:0003796, GO:0016998, GO:0019835, GO:0042742, GO:0009253, GO:0044659, IPR034690, IPR002196, IPR023346, IPR023347, IPR001165, P07550, Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.G-protein coupled receptors, family A",1,7XK9,Mutant,P00720,UniProt,C13 H19 N O3,237.295,GJ6,"(5R,6R)-6-(propan-2-ylamino)-5,6,7,8-tetrahydronaphthalene-1,2,5-triol",CC(C)NC1CCc2c(ccc(c2O)O)C1O,3
7XKA,,,,,,7XKA,Structure of human beta2 adrenergic receptor bound to constrained epinephrine,Structure of human beta2 adrenergic receptor bound to constrained epinephrine,MEMBRANE PROTEIN,E,3.2.1.17,"GO:0016324, GO:0030669, GO:0005769, GO:0005768, GO:0010008, GO:0005794, GO:0005764, GO:0016020, GO:0005634, GO:0005886, GO:0043235, GO:0008179, GO:0001540, GO:0004941, GO:0004930, GO:0042802, GO:0051380, GO:0015459, GO:0042803, GO:0044877, GO:0007190, GO:0007171, GO:0071880, GO:0007188, GO:0071875, GO:0045453, GO:0050873, GO:0007166, GO:1904646, GO:0002032, GO:0002024, GO:0008333, GO:0031649, GO:0040015, GO:0045986, GO:0002025, GO:2000969, GO:1901098, GO:0030501, GO:2000481, GO:0120162, GO:1904504, GO:0043410, GO:0061885, GO:0010739, GO:0071902, GO:0045944, GO:0006898, GO:0002028, GO:0009409, GO:1990911, GO:0006939, GO:0006366, IPR002233, IPR000332, IPR000276, IPR017452, GO:0030430, GO:0003796, GO:0016998, GO:0019835, GO:0042742, GO:0009253, GO:0044659, IPR034690, IPR002196, IPR023346, IPR023347, IPR001165, P07550, Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.G-protein coupled receptors, family A",1,7XKA,Mutant,P00720,UniProt,C11 H15 N O3,209.242,G1I,"(5R,6R)-6-(methylamino)-5,6,7,8-tetrahydronaphthalene-1,2,5-triol",CNC1CCc2c(ccc(c2O)O)C1O,3
7XS8,,,,,,7XS8,Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants.,Crystal structure of SARS-CoV-2 spike receptor binding domain bound with P5S-1H1 Fab,VIRAL PROTEIN/IMMUNE SYSTEM,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",2,7XS8,wildtype,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7XUO,,,,,,7XUO,Structures of the human Wilson disease copper transporter ATP7B.,Structure of ATP7B C983S/C985S/D1027A mutant with cisplatin in presence of ATOX1,"TRANSLOCATE,METAL TRANSPORT","ATP7B, PWD, WC1, WND",7.2.2.8,"GO:0005794, GO:0000139, GO:0005770, GO:0016020, GO:0005739, GO:0005886, GO:0032588, GO:0005524, GO:0016887, GO:0005507, GO:0005375, GO:0043682, GO:0140581, GO:0006878, GO:0006882, GO:0060003, GO:0055070, GO:0015677, GO:0006825, GO:0051649, GO:0034220, GO:0007595, GO:0015680, GO:0046688, GO:0051208, GO:1990961, IPR023299, IPR018303, IPR023298, IPR008250, IPR036412, IPR023214, IPR017969, IPR006122, IPR006121, IPR036163, IPR027256, IPR001757, IPR044492, P35670, Transmembrane.Alpha-helical polytopic.P-type ATPase (P-ATPase).Copper-transporting P-type ATPase, Generic PDBTM",1,7XUO,Mutant,P35670,UniProt,Pt,195.078,PT,PLATINUM (II) ION,[Pt+2],2
7Y0H,,,,,,7Y0H,Cryo-EM structure of human IgM-Fc in complex with the J chain and the P. falciparum VAR2CSA FCR3,Cryo-EM structure of human IgM-Fc in complex with the J chain and the P. falciparum VAR2CSA FCR3,IMMUNE SYSTEM,IGHM,,"GO:0072562, GO:0009986, GO:0009897, GO:0070062, GO:0005615, GO:0071757, GO:0071753, GO:0042571, GO:0071756, GO:0005886, GO:0003823, GO:0002250, GO:0019731, GO:0050853, GO:0006958, GO:0042742, GO:0050829, GO:0045087, GO:0006911, GO:0006910, GO:0050871, IPR007110, IPR036179, IPR013783, IPR003006, IPR003597, P01871",1,7Y0H,wildtype,P01871,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7Y7W,,,,,,7Y7W,Structural investigation of the GABA transporter GAT1,Cryo-EM structure of human GABA transporter GAT1 bound with GABA in NaCl solution in an inward-occluded state at 2.4 angstrom,TRANSPORT PROTEIN,"SLC6A1, GABATR, GABT1, GAT1",,"GO:0070161, GO:0030424, GO:0009986, GO:0098982, GO:0016020, GO:0043005, GO:0043025, GO:0005886, GO:0015185, GO:0005332, GO:0042802, GO:0046872, GO:0015378, GO:0008306, GO:0007268, GO:1902476, GO:0051939, GO:0051936, GO:0098658, GO:0007613, GO:0032229, GO:0014054, GO:0051592, GO:0042220, GO:0032355, GO:0010035, GO:0010288, GO:0014074, GO:0009744, GO:0009636, GO:0098719, GO:0035725, GO:0050808, GO:0150104, IPR000175, IPR002980, IPR037272, P30531, Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Neurotransmitter: sodium symporter, Generic PDBTM",1,7Y7W,wildtype,P30531,UniProt,C4 H9 N O2,103.12,ABU,GAMMA-AMINO-BUTANOIC ACID,C(CC(=O)O)CN,2
7Y7Y,,,,,,7Y7Y,Structural investigation of the GABA transporter GAT1,Cryo-EM structure of human GABA transporter GAT1 bound with nipecotic acid in NaCl solution in an inward-occluded state at 2.4 angstrom,TRANSPORT PROTEIN,"SLC6A1, GABATR, GABT1, GAT1",,"GO:0070161, GO:0030424, GO:0009986, GO:0098982, GO:0016020, GO:0043005, GO:0043025, GO:0005886, GO:0015185, GO:0005332, GO:0042802, GO:0046872, GO:0015378, GO:0008306, GO:0007268, GO:1902476, GO:0051939, GO:0051936, GO:0098658, GO:0007613, GO:0032229, GO:0014054, GO:0051592, GO:0042220, GO:0032355, GO:0010035, GO:0010288, GO:0014074, GO:0009744, GO:0009636, GO:0098719, GO:0035725, GO:0050808, GO:0150104, IPR000175, IPR002980, IPR037272, P30531, Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Neurotransmitter: sodium symporter, Generic PDBTM",1,7Y7Y,wildtype,P30531,UniProt,C6 H11 N O2,129.157,ID7,(3R)-piperidine-3-carboxylic acid,C1CC(CNC1)C(=O)O,2
7Y7Z,,,,,,7Y7Z,Structural investigation of the GABA transporter GAT1,Cryo-EM structure of human GABA transporter GAT1 bound with tiagabine in NaCl solution in an inward-open state at 3.2 angstrom,TRANSPORT PROTEIN,"SLC6A1, GABATR, GABT1, GAT1",,"GO:0070161, GO:0030424, GO:0009986, GO:0098982, GO:0016020, GO:0043005, GO:0043025, GO:0005886, GO:0015185, GO:0005332, GO:0042802, GO:0046872, GO:0015378, GO:0008306, GO:0007268, GO:1902476, GO:0051939, GO:0051936, GO:0098658, GO:0007613, GO:0032229, GO:0014054, GO:0051592, GO:0042220, GO:0032355, GO:0010035, GO:0010288, GO:0014074, GO:0009744, GO:0009636, GO:0098719, GO:0035725, GO:0050808, GO:0150104, IPR000175, IPR002980, IPR037272, P30531, Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Neurotransmitter: sodium symporter, Generic PDBTM",1,7Y7Z,wildtype,P30531,UniProt,C20 H25 N O2 S2,375.548,TGI,Tiagabine,Cc1ccsc1C(=CCCN2CCCC(C2)C(=O)O)c3c(ccs3)C,2
7YF2,,,,,,7YF2,Molecular basis for METTL9-mediated N1-histidine methylation,Crystal structure of METTL9 in complex with unmethylated SLC39A5 peptide and SAH,TRANSFERASE,"METTL9, DREV, CGI-81",2.1.1,"GO:0005783, GO:0005739, GO:0106370, IPR007884, IPR029063, Q9H1A3",1,7YF2,Mutant,Q9H1A3,UniProt,C14 H20 N6 O5 S,384.411,SAH,S-ADENOSYL-L-HOMOCYSTEINE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)CSCCC(C(=O)O)N)O)O)N,3
7YF3,,,,,,7YF3,Molecular basis for METTL9-mediated N1-histidine methylation,Crystal structure of METTL9 in complex with unmethylated S100A9 peptide and SAH,TRANSFERASE,"METTL9, DREV, CGI-81",2.1.1,"GO:0005783, GO:0005739, GO:0106370, IPR007884, IPR029063, Q9H1A3",1,7YF3,Mutant,Q9H1A3,UniProt,C14 H20 N6 O5 S,384.411,SAH,S-ADENOSYL-L-HOMOCYSTEINE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)CSCCC(C(=O)O)N)O)O)N,3
7YF4,,,,,,7YF4,Molecular basis for METTL9-mediated N1-histidine methylation,Crystal structure of METTL9 in complex with SLC39A5 mutant peptide and SAH,TRANSFERASE,"METTL9, DREV, CGI-81",2.1.1,"GO:0005783, GO:0005739, GO:0106370, IPR007884, IPR029063, Q9H1A3",1,7YF4,Mutant,Q9H1A3,UniProt,C14 H20 N6 O5 S,384.411,SAH,S-ADENOSYL-L-HOMOCYSTEINE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)CSCCC(C(=O)O)N)O)O)N,3
7YFF,,,,,,7YFF,Distinct structure and gating mechanism in diverse NMDA receptors with GluN2C and GluN2D subunits.,Structure of GluN1a-GluN2D NMDA receptor in complex with agonist glycine and competitive antagonist CPP.,ELECTRON TRANSPORT,"GRIN2D, GluN2D, NMDAR2D",,"GO:0070161, GO:0005789, GO:0098978, GO:0098686, GO:0017146, GO:0005886, GO:0098839, GO:0045211, GO:0016595, GO:0022849, GO:0004970, GO:0015276, GO:0042165, GO:0004972, GO:0038023, GO:1904315, GO:0008344, GO:0007420, GO:0097553, GO:0098976, GO:0060079, GO:0060291, GO:2000463, GO:0051968, GO:1904062, GO:0048168, GO:0051930, GO:0048167, GO:0001964, GO:0035249, IPR001828, IPR019594, IPR001508, IPR001320, IPR028082, O15399, Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Glutamate-gated Ion Channel (GIC) family, Generic PDBTM",2,7YFF,wildtype,O15399,UniProt,C8 H17 N2 O5 P,252.205,7RC,(2R)-4-(3-phosphonopropyl)piperazine-2-carboxylic acid,C1CN(CC(N1)C(=O)O)CCCP(=O)(O)O,6
7YFL,,,,,,7YFL,Distinct structure and gating mechanism in diverse NMDA receptors with GluN2C and GluN2D subunits.,Structure of GluN1a-GluN2D NMDA receptor in complex with agonists glycine and glutamate.,ELECTRON TRANSPORT,"GRIN2D, GluN2D, NMDAR2D",,"GO:0070161, GO:0005789, GO:0098978, GO:0098686, GO:0017146, GO:0005886, GO:0098839, GO:0045211, GO:0016595, GO:0022849, GO:0004970, GO:0015276, GO:0042165, GO:0004972, GO:0038023, GO:1904315, GO:0008344, GO:0007420, GO:0097553, GO:0098976, GO:0060079, GO:0060291, GO:2000463, GO:0051968, GO:1904062, GO:0048168, GO:0051930, GO:0048167, GO:0001964, GO:0035249, IPR001828, IPR019594, IPR001508, IPR001320, IPR028082, O15399, Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Glutamate-gated Ion Channel (GIC) family, Generic PDBTM",2,7YFL,wildtype,O15399,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7YFR,,,,,,7YFR,Distinct structure and gating mechanism in diverse NMDA receptors with GluN2C and GluN2D subunits.,Structure of GluN1a E698C-GluN2D NMDA receptor in cystines non-crosslinked state.,ELECTRON TRANSPORT,"GRIN2D, GluN2D, NMDAR2D",,"GO:0070161, GO:0005789, GO:0098978, GO:0098686, GO:0017146, GO:0005886, GO:0098839, GO:0045211, GO:0016595, GO:0022849, GO:0004970, GO:0015276, GO:0042165, GO:0004972, GO:0038023, GO:1904315, GO:0008344, GO:0007420, GO:0097553, GO:0098976, GO:0060079, GO:0060291, GO:2000463, GO:0051968, GO:1904062, GO:0048168, GO:0051930, GO:0048167, GO:0001964, GO:0035249, IPR001828, IPR019594, IPR001508, IPR001320, IPR028082, O15399, Generic PDBTM",2,7YFR,Mutant,O15399,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7YKD,,,,,,7YKD,Cryo-EM structure of the human chemerin receptor 1-Gi protein complex bound to the C-terminal nonapeptide of chemerin.,Cryo-EM structure of the human chemerin receptor 1 complex with the C-terminal nonapeptide of chemerin,PEPTIDE BINDING PROTEIN,GNG2,,"GO:0070062, GO:0005834, GO:0016020, GO:0005886, GO:0031681, GO:0007191, GO:0071870, GO:0071380, GO:0048144, GO:0007186, IPR015898, IPR036284, IPR001770, P59768, Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.G-protein coupled receptors, family A, Generic PDBTM",5,7YKD,Mutant,P59768,UniProt,C27 H46 O,386.654,CLR,CHOLESTEROL,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C,7
7YV4,,,,,,7YV4,Farrerol directly activates the deubiqutinase UCHL3 to promote DNA repair and reprogramming when mediated by somatic cell nuclear transfer.,Crystal structure of human UCHL3 in complex with Farrerol,HYDROLASE,UCHL3,3.4.19.12,"GO:0005737, GO:0005829, GO:0005654, GO:0004843, GO:0019784, GO:0008233, GO:0043130, GO:0043687, GO:0030163, GO:0016579, GO:0016567, GO:0006511, IPR038765, IPR001578, IPR036959, P15374",1,7YV4,wildtype,P15374,UniProt,C17 H16 O5,300.306,JXY,"(2~{S})-2-(4-hydroxyphenyl)-6,8-dimethyl-5,7-bis(oxidanyl)-2,3-dihydrochromen-4-one",Cc1c(c(c2c(c1O)C(=O)CC(O2)c3ccc(cc3)O)C)O,2
7ZI4,,,,,,7ZI4,Cryo-EM structure of the human INO80 complex bound to a WT nucleosome,Cryo-EM structure of the human INO80 complex bound to a WT nucleosome,DNA BINDING PROTEIN,"HIST1H2BJ, H2BFR, H2BC11",,"GO:0043505, GO:0005829, GO:0005615, GO:0005654, GO:0000786, GO:0005634, GO:0003677, GO:0001530, GO:0046982, GO:0030527, GO:0019731, GO:0061844, GO:0050829, GO:0050830, GO:0002227, GO:0031640, GO:0010804, GO:0006334, GO:0061644, IPR009072, IPR007125, IPR000558, P06899",11,7ZI4,wildtype,P06899,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,13
7ZLM,,,,,,7ZLM,"Structure-based design of a phosphotyrosine-masked, cell-penetrant small molecule covalently targeting Cys111 on the E3 ligase SOCS2",Crystal structure of SOCS2:ElonginB:ElonginC in complex with compound MN551,LIGASE,"SOCS2, CIS2, SSI2, STATI2",,"GO:0005737, GO:0005829, GO:0005942, GO:0046935, GO:0005131, GO:0005159, GO:0008269, GO:0032870, GO:0060396, GO:0035556, GO:0007595, GO:0060749, GO:0043066, GO:0040015, GO:0046426, GO:0046854, GO:0045666, GO:0016567, GO:0007259, GO:0001558, GO:0009966, GO:0032355, IPR000980, IPR036860, IPR028410, IPR035862, IPR001496, IPR036036, O14508",1,7ZLM,wildtype,O14508,UniProt,C26 H26 Cl F N3 O7 P,577.926,JIH,[4-[(2~{S})-3-[[3-(2-chloranylethanoylamino)phenyl]methylamino]-2-[2-(4-fluorophenyl)ethanoylamino]-3-oxidanylidene-propyl]phenyl] dihydrogen phosphate,c1cc(cc(c1)NC(=O)CCl)CNC(=O)C(Cc2ccc(cc2)OP(=O)(O)O)NC(=O)Cc3ccc(cc3)F,4
7ZLN,,,,,,7ZLN,"Structure-based design of a phosphotyrosine-masked, cell-penetrant small molecule covalently targeting Cys111 on the E3 ligase SOCS2",Crystal structure of SOCS2:ElonginB:ElonginC in complex with compound 11,LIGASE,"SOCS2, CIS2, SSI2, STATI2",,"GO:0005737, GO:0005829, GO:0005942, GO:0046935, GO:0005131, GO:0005159, GO:0008269, GO:0032870, GO:0060396, GO:0035556, GO:0007595, GO:0060749, GO:0043066, GO:0040015, GO:0046426, GO:0046854, GO:0045666, GO:0016567, GO:0007259, GO:0001558, GO:0009966, GO:0032355, IPR000980, IPR036860, IPR028410, IPR035862, IPR001496, IPR036036, O14508",1,7ZLN,wildtype,O14508,UniProt,C25 H25 F2 N2 O6 P,518.446,JI9,[4-[(2~{S})-3-[(4-fluoranyl-3-methyl-phenyl)methylamino]-2-[2-(4-fluorophenyl)ethanoylamino]-3-oxidanylidene-propyl]phenyl] dihydrogen phosphate,Cc1cc(ccc1F)CNC(=O)C(Cc2ccc(cc2)OP(=O)(O)O)NC(=O)Cc3ccc(cc3)F,4
7ZLO,,,,,,7ZLO,"Structure-based design of a phosphotyrosine-masked, cell-penetrant small molecule covalently targeting Cys111 on the E3 ligase SOCS2",Crystal structure of SOCS2:ElonginB:ElonginC in complex with compound 12,LIGASE,"SOCS2, CIS2, SSI2, STATI2",,"GO:0005737, GO:0005829, GO:0005942, GO:0046935, GO:0005131, GO:0005159, GO:0008269, GO:0032870, GO:0060396, GO:0035556, GO:0007595, GO:0060749, GO:0043066, GO:0040015, GO:0046426, GO:0046854, GO:0045666, GO:0016567, GO:0007259, GO:0001558, GO:0009966, GO:0032355, IPR000980, IPR036860, IPR028410, IPR035862, IPR001496, IPR036036, O14508",1,7ZLO,wildtype,O14508,UniProt,C26 H27 F2 N2 O6 P,532.473,JI0,[4-[(2~{S})-3-[(3-ethyl-4-fluoranyl-phenyl)methylamino]-2-[2-(4-fluorophenyl)ethanoylamino]-3-oxidanylidene-propyl]phenyl] dihydrogen phosphate,CCc1cc(ccc1F)CNC(=O)C(Cc2ccc(cc2)OP(=O)(O)O)NC(=O)Cc3ccc(cc3)F,4
7ZLP,,,,,,7ZLP,"Structure-based design of a phosphotyrosine-masked, cell-penetrant small molecule covalently targeting Cys111 on the E3 ligase SOCS2",Crystal structure of SOCS2:ElonginB:ElonginC in complex with compound 9,LIGASE,"SOCS2, CIS2, SSI2, STATI2",,"GO:0005737, GO:0005829, GO:0005942, GO:0046935, GO:0005131, GO:0005159, GO:0008269, GO:0032870, GO:0060396, GO:0035556, GO:0007595, GO:0060749, GO:0043066, GO:0040015, GO:0046426, GO:0046854, GO:0045666, GO:0016567, GO:0007259, GO:0001558, GO:0009966, GO:0032355, IPR000980, IPR036860, IPR028410, IPR035862, IPR001496, IPR036036, O14508",1,7ZLP,wildtype,O14508,UniProt,C24 H23 F2 N2 O6 P,504.42,JHR,[4-[(2~{S})-2-[2-(4-fluorophenyl)ethanoylamino]-3-[(4-fluorophenyl)methylamino]-3-oxidanylidene-propyl]phenyl] dihydrogen phosphate,c1cc(ccc1CC(C(=O)NCc2ccc(cc2)F)NC(=O)Cc3ccc(cc3)F)OP(=O)(O)O,4
7ZLR,,,,,,7ZLR,"Structure-based design of a phosphotyrosine-masked, cell-penetrant small molecule covalently targeting Cys111 on the E3 ligase SOCS2",Crystal structure of SOCS2:ElonginB:ElonginC in complex with compound 13,LIGASE,"SOCS2, CIS2, SSI2, STATI2",,"GO:0005737, GO:0005829, GO:0005942, GO:0046935, GO:0005131, GO:0005159, GO:0008269, GO:0032870, GO:0060396, GO:0035556, GO:0007595, GO:0060749, GO:0043066, GO:0040015, GO:0046426, GO:0046854, GO:0045666, GO:0016567, GO:0007259, GO:0001558, GO:0009966, GO:0032355, IPR000980, IPR036860, IPR028410, IPR035862, IPR001496, IPR036036, O14508",1,7ZLR,wildtype,O14508,UniProt,C27 H27 F2 N2 O6 P,544.484,JH9,[4-[(2~{S})-3-[(4-fluoranyl-3-prop-2-enyl-phenyl)methylamino]-2-[2-(4-fluorophenyl)ethanoylamino]-3-oxidanylidene-propyl]phenyl] dihydrogen phosphate,C=CCc1cc(ccc1F)CNC(=O)C(Cc2ccc(cc2)OP(=O)(O)O)NC(=O)Cc3ccc(cc3)F,4
7ZLS,,,,,,7ZLS,"Structure-based design of a phosphotyrosine-masked, cell-penetrant small molecule covalently targeting Cys111 on the E3 ligase SOCS2",co-crystal structure of SOCS2:ElonginB:ElonginC in complex with compound 13,LIGASE,"ELOB, TCEB2",,"GO:0031462, GO:0031466, GO:0005829, GO:0070449, GO:0005654, GO:0030891, GO:0001222, GO:0031625, GO:0032436, GO:0016567, GO:0065003, GO:0006368, GO:0006367, IPR039049, IPR000626, IPR029071, Q15370",2,7ZLS,wildtype,Q15370,UniProt,C27 H27 F2 N2 O6 P,544.484,JH9,[4-[(2~{S})-3-[(4-fluoranyl-3-prop-2-enyl-phenyl)methylamino]-2-[2-(4-fluorophenyl)ethanoylamino]-3-oxidanylidene-propyl]phenyl] dihydrogen phosphate,C=CCc1cc(ccc1F)CNC(=O)C(Cc2ccc(cc2)OP(=O)(O)O)NC(=O)Cc3ccc(cc3)F,5
7ZLY,,,,,,7ZLY,Structural insights into the human niacin receptor HCA2-G i signalling complex.,Crystal structure of human GPCR Niacin receptor (HCA2) expressed from Spodoptera frugiperda,MEMBRANE PROTEIN,"HCAR2, GPR109A, HCA2, HM74A, NIACR1",,"GO:0042597, GO:0009055, GO:0020037, GO:0005506, IPR009155, IPR010980, GO:0030054, GO:0005886, GO:0004930, GO:0070553, GO:0007186, GO:0050995, GO:0001781, GO:0070165, GO:0033031, IPR000276, IPR017452, IPR028017, Q8TDS4, Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.G-protein coupled receptors, family A, Generic PDBTM",1,7ZLY,wildtype,Q8TDS4,UniProt,C18 H34 O2,282.461,OLA,OLEIC ACID,CCCCCCCCC=CCCCCCCCC(=O)O,2
7ZLY,,,,,,7ZLY,Structural insights into the human niacin receptor HCA2-G i signalling complex.,Crystal structure of human GPCR Niacin receptor (HCA2) expressed from Spodoptera frugiperda,MEMBRANE PROTEIN,cybC,,"GO:0042597, GO:0009055, GO:0020037, GO:0005506, IPR009155, IPR010980, GO:0030054, GO:0005886, GO:0004930, GO:0070553, GO:0007186, GO:0050995, GO:0001781, GO:0070165, GO:0033031, IPR000276, IPR017452, IPR028017, Q8TDS4, Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.G-protein coupled receptors, family A, Generic PDBTM",1,7ZLY,wildtype,P0ABE7,UniProt,C21 H40 O4,356.54,OLC,"(2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate",CCCCCCCCC=CCCCCCCCC(=O)OCC(CO)O,3
8A62,,,,,,8A62,A Systematic Approach to the Discovery of Protein-Protein Interaction Stabilizers.,Small molecule stabilizer (compound 2) for FOXO1 and 14-3-3,STRUCTURAL PROTEIN,"FOXO1, FKHR, FOXO1A",,"GO:0000785, GO:0005737, GO:0005829, GO:0005739, GO:0005654, GO:0005634, GO:0008013, GO:0003682, GO:0031490, GO:0001228, GO:0003700, GO:0000981, GO:0001227, GO:1990841, GO:0051721, GO:0000978, GO:0043565, GO:0031625, GO:0006915, GO:0006914, GO:0001568, GO:0060070, GO:0001678, GO:0070417, GO:0006974, GO:0071455, GO:0032869, GO:0071732, GO:0034599, GO:0009267, GO:0097009, GO:0045444, GO:0008286, GO:0043066, GO:0090090, GO:1903243, GO:0045599, GO:0046676, GO:0032873, GO:0045892, GO:0097150, GO:0043065, GO:0010508, GO:0045722, GO:0045732, GO:0045944, GO:0045893, GO:0006473, GO:2000177, GO:2000377, GO:0006357, GO:0070542, GO:0001659, IPR001766, IPR032067, IPR032068, IPR030456, IPR036388, IPR036390, Q12778",2,8A62,Mutant,Q12778,UniProt,C19 H27 Cl2 N3 O3 S2,480.472,L7L,"(3~{S})-1-[3,5-bis(chloranyl)-4-oxidanyl-phenyl]carbonyl-~{N}-[2-[2-(dimethylamino)ethyldisulfanyl]ethyl]piperidine-3-carboxamide",CN(C)CCSSCCNC(=O)C1CCCN(C1)C(=O)c2cc(c(c(c2)Cl)O)Cl,4
8A65,,,,,,8A65,A Systematic Approach to the Discovery of Protein-Protein Interaction Stabilizers.,Small molecule stabilizer (compound 3) for FOXO1 and 14-3-3,STRUCTURAL PROTEIN,"FOXO1, FKHR, FOXO1A",,"GO:0000785, GO:0005737, GO:0005829, GO:0005739, GO:0005654, GO:0005634, GO:0008013, GO:0003682, GO:0031490, GO:0001228, GO:0003700, GO:0000981, GO:0001227, GO:1990841, GO:0051721, GO:0000978, GO:0043565, GO:0031625, GO:0006915, GO:0006914, GO:0001568, GO:0060070, GO:0001678, GO:0070417, GO:0006974, GO:0071455, GO:0032869, GO:0071732, GO:0034599, GO:0009267, GO:0097009, GO:0045444, GO:0008286, GO:0043066, GO:0090090, GO:1903243, GO:0045599, GO:0046676, GO:0032873, GO:0045892, GO:0097150, GO:0043065, GO:0010508, GO:0045722, GO:0045732, GO:0045944, GO:0045893, GO:0006473, GO:2000177, GO:2000377, GO:0006357, GO:0070542, GO:0001659, IPR001766, IPR032067, IPR032068, IPR030456, IPR036388, IPR036390, Q12778",2,8A65,wildtype,Q12778,UniProt,C19 H28 Cl2 N4 O2 S2,479.487,L70,"(3~{S})-1-[2-azanyl-3,5-bis(chloranyl)phenyl]carbonyl-~{N}-[2-[2-(dimethylamino)ethyldisulfanyl]ethyl]piperidine-3-carboxamide",CN(C)CCSSCCNC(=O)C1CCCN(C1)C(=O)c2cc(cc(c2N)Cl)Cl,4
8ALK,,,,,,8ALK,Dephosphocholination by Legionella effector Lem3 functions through remodelling of the switch II region of Rab1b.,Structure of the Legionella phosphocholine hydrolase Lem3 in complex with its substrate Rab1,HYDROLASE,"lem3, lpg0696",3.1.3,"GO:0005576, GO:0030430, GO:0044606, GO:0043087, IPR036457",1,8ALK,Mutant,Q5ZXN5,UniProt,C18 H33 Cl N5 O12 P2,608.881,OJU,"2-[[[5-(4-azanyl-2-oxidanylidene-pyrimidin-1-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]oxy-oxidanyl-phosphoryl]oxyethyl-[3-(2-chloranylethanoylamino)propyl]-dimethyl-azanium",C[N+](C)(CCCNC(=O)CCl)CCOP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)N2C=CC(=NC2=O)N)O)O,5
8BPE,,,,,,8BPE,Structural basis for Fc receptor recognition of immunoglobulin M.,8:1 binding of FcMR on IgM pentameric core,IMMUNE SYSTEM,"FCMR, FAIM3, TOSO",,"GO:0005576, GO:0005886, GO:0004888, GO:0006968, GO:0002376, GO:0043066, IPR036179, IPR013783, IPR003599, IPR013106, O60667",1,8BPE,wildtype,O60667,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8BPF,,,,,,8BPF,Structural basis for Fc receptor recognition of immunoglobulin M.,FcMR binding at subunit Fcu1 of IgM pentamer,IMMUNE SYSTEM,"FCMR, FAIM3, TOSO",,"GO:0005576, GO:0005886, GO:0004888, GO:0006968, GO:0002376, GO:0043066, IPR036179, IPR013783, IPR003599, IPR013106, O60667",1,8BPF,wildtype,O60667,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8BPG,,,,,,8BPG,Structural basis for Fc receptor recognition of immunoglobulin M.,FcMR binding at subunit Fcu3 of IgM pentamer,IMMUNE SYSTEM,"FCMR, FAIM3, TOSO",,"GO:0005576, GO:0005886, GO:0004888, GO:0006968, GO:0002376, GO:0043066, IPR036179, IPR013783, IPR003599, IPR013106, O60667",1,8BPG,wildtype,O60667,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
8CAA,,,,,,8CAA,Optimization of a Class of Dihydrobenzofurane Analogs toward Orally Efficacious YAP-TEAD Protein-Protein Interaction Inhibitors.,Crystal structure of TEAD4 in complex with YTP-13,TRANSCRIPTION,"TEAD4, RTEF1, TCF13L1, TEF3",,"GO:0000785, GO:0005737, GO:0005654, GO:0005634, GO:0032993, GO:0005667, GO:0001228, GO:0003700, GO:0000981, GO:0000978, GO:0001708, GO:0007566, GO:0048568, GO:0035329, GO:0007517, GO:1902459, GO:0006357, GO:0001501, GO:0006351, GO:0001830, IPR000818, IPR038096, IPR027255, IPR016361, IPR041086, Q15561",1,8CAA,wildtype,Q15561,UniProt,C29 H27 Cl F4 N2 O4,578.982,U3F,4-[bis(fluoranyl)methoxy]-2-[(2~{S})-5-chloranyl-6-fluoranyl-2-[[(4-oxidanylcyclohexyl)amino]methyl]-2-phenyl-3~{H}-1-benzofuran-4-yl]-3-fluoranyl-benzamide,c1ccc(cc1)C2(Cc3c(cc(c(c3c4c(ccc(c4F)OC(F)F)C(=O)N)Cl)F)O2)CNC5CCC(CC5)O,2
8DNF,,,,,,8DNF,Structural insights into actin isoforms.,Cryo-EM structure of nonmuscle gamma-actin,STRUCTURAL PROTEIN,"ACTG1, ACTG",,"GO:0005884, GO:0043296, GO:0120220, GO:0072562, GO:0044305, GO:0005911, GO:0005856, GO:0005829, GO:0097433, GO:0070062, GO:0005615, GO:0031941, GO:0005925, GO:0016020, GO:0030016, GO:0005634, GO:0045335, GO:0005886, GO:0098871, GO:0099143, GO:0098685, GO:0005524, GO:0042802, GO:0005522, GO:0005200, GO:0098973, GO:0031625, GO:0001525, GO:0071346, GO:0035633, GO:0001738, GO:0070527, GO:0030335, GO:0010628, GO:0090303, GO:1902396, GO:0051893, GO:0051492, GO:0150111, GO:0051592, GO:0009612, GO:0001895, GO:0045214, GO:0048488, GO:0120192, IPR004000, IPR020902, IPR004001, IPR043129, P63261",1,8DNF,Mutant,P63261,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8DV3,,,,,,8DV3,alpha beta T-cell receptor recognition of self-phosphatidylinositol presented by CD1b.,Crystal structure of human CD1b presenting Phosphatidylinositol C34:1,IMMUNE SYSTEM,CD1B,,"GO:0009986, GO:0005829, GO:0010008, GO:0009897, GO:0005615, GO:0005794, GO:0043231, GO:0005765, GO:0005886, GO:0030883, GO:0030884, GO:0071723, GO:0002250, GO:0048006, GO:0048007, GO:0001916, IPR007110, IPR036179, IPR013783, IPR003597, IPR011161, IPR037055, IPR011162, P29016",1,8DV3,wildtype,P29016,UniProt,C43 H80 O13 P,836.061,PIE,"1,2-DIACYL-SN-GLYCERO-3-PHOSPHOINOSITOL",CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OC1C(C(C(C(C1O)O)O)O)O)OC(=O)CCCCCCCC=CCCCCCCCC,10
8DV3,,,,,,8DV3,alpha beta T-cell receptor recognition of self-phosphatidylinositol presented by CD1b.,Crystal structure of human CD1b presenting Phosphatidylinositol C34:1,IMMUNE SYSTEM,"B2M, CDABP0092, HDCMA22P",,"GO:0005829, GO:0031905, GO:0031901, GO:0005788, GO:0012507, GO:0009897, GO:0070062, GO:0005576, GO:0005615, GO:0005925, GO:0005794, GO:0000139, GO:1990712, GO:0016020, GO:0042824, GO:0042612, GO:0042613, GO:0030670, GO:0005886, GO:0055038, GO:0035580, GO:1904724, GO:0042802, GO:0023026, GO:0042803, GO:1990000, GO:0019731, GO:0019885, GO:0019886, GO:0002481, GO:0061844, GO:0071281, GO:0071283, GO:0071222, GO:0071316, GO:0050829, GO:0050830, GO:0045087, GO:0006826, GO:0007611, GO:0050680, GO:2000978, GO:0050768, GO:0010977, GO:1900121, GO:0002503, GO:2000774, GO:1904434, GO:0032092, GO:1900122, GO:0048260, GO:0050870, GO:0002726, GO:0001916, GO:1904437, GO:0051289, GO:0042026, GO:0045646, GO:0034756, GO:0003254, GO:0002237, GO:0001895, GO:0007608, GO:0033077, GO:0001913, IPR015707, IPR007110, IPR036179, IPR013783, IPR003006, IPR003597, P61769",2,8DV3,wildtype,P61769,UniProt,C40 H80 O2,593.062,6UL,TETRACOSYL PALMITATE,CCCCCCCCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC,8
8DV4,,,,,,8DV4,alpha beta T-cell receptor recognition of self-phosphatidylinositol presented by CD1b.,Crystal structure of the BC8B TCR-CD1b-PI complex,IMMUNE SYSTEM,"B2M, CDABP0092, HDCMA22P",,"GO:0005829, GO:0031905, GO:0031901, GO:0005788, GO:0012507, GO:0009897, GO:0070062, GO:0005576, GO:0005615, GO:0005925, GO:0005794, GO:0000139, GO:1990712, GO:0016020, GO:0042824, GO:0042612, GO:0042613, GO:0030670, GO:0005886, GO:0055038, GO:0035580, GO:1904724, GO:0042802, GO:0023026, GO:0042803, GO:1990000, GO:0019731, GO:0019885, GO:0019886, GO:0002481, GO:0061844, GO:0071281, GO:0071283, GO:0071222, GO:0071316, GO:0050829, GO:0050830, GO:0045087, GO:0006826, GO:0007611, GO:0050680, GO:2000978, GO:0050768, GO:0010977, GO:1900121, GO:0002503, GO:2000774, GO:1904434, GO:0032092, GO:1900122, GO:0048260, GO:0050870, GO:0002726, GO:0001916, GO:1904437, GO:0051289, GO:0042026, GO:0045646, GO:0034756, GO:0003254, GO:0002237, GO:0001895, GO:0007608, GO:0033077, GO:0001913, IPR015707, IPR007110, IPR036179, IPR013783, IPR003006, IPR003597, P61769",2,8DV4,wildtype,P61769,UniProt,C43 H80 O13 P,836.061,PIE,"1,2-DIACYL-SN-GLYCERO-3-PHOSPHOINOSITOL",CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OC1C(C(C(C(C1O)O)O)O)O)OC(=O)CCCCCCCC=CCCCCCCCC,14
8DV4,,,,,,8DV4,alpha beta T-cell receptor recognition of self-phosphatidylinositol presented by CD1b.,Crystal structure of the BC8B TCR-CD1b-PI complex,IMMUNE SYSTEM,"B2M, CDABP0092, HDCMA22P",,"GO:0005829, GO:0031905, GO:0031901, GO:0005788, GO:0012507, GO:0009897, GO:0070062, GO:0005576, GO:0005615, GO:0005925, GO:0005794, GO:0000139, GO:1990712, GO:0016020, GO:0042824, GO:0042612, GO:0042613, GO:0030670, GO:0005886, GO:0055038, GO:0035580, GO:1904724, GO:0042802, GO:0023026, GO:0042803, GO:1990000, GO:0019731, GO:0019885, GO:0019886, GO:0002481, GO:0061844, GO:0071281, GO:0071283, GO:0071222, GO:0071316, GO:0050829, GO:0050830, GO:0045087, GO:0006826, GO:0007611, GO:0050680, GO:2000978, GO:0050768, GO:0010977, GO:1900121, GO:0002503, GO:2000774, GO:1904434, GO:0032092, GO:1900122, GO:0048260, GO:0050870, GO:0002726, GO:0001916, GO:1904437, GO:0051289, GO:0042026, GO:0045646, GO:0034756, GO:0003254, GO:0002237, GO:0001895, GO:0007608, GO:0033077, GO:0001913, IPR015707, IPR007110, IPR036179, IPR013783, IPR003006, IPR003597, P61769",4,8DV4,wildtype,P61769,UniProt,C42 H84 O2,621.115,CUY,tetracosyl octadecanoate,CCCCCCCCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC,11
8F0P,,,,,,8F0P,Cryo-EM reveals an unprecedented binding site for Na V 1.7 inhibitors enabling rational design of potent hybrid inhibitors.,Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the hybrid inhibitor GNE-1305,MEMBRANE PROTEIN/INHIBITOR,SCN9A,,"GO:0030424, GO:0001518, GO:0031402, GO:0005244, GO:0005248, GO:0061368, GO:0006954, GO:0086010, GO:0045759, GO:0019228, GO:0009791, GO:0034765, GO:0009409, GO:0009408, GO:0009636, GO:0019233, GO:0035725, GO:0006814, IPR005821, IPR000048, IPR001696, IPR044564, IPR010526, IPR024583, IPR028803, IPR043203, IPR027359, IPR031649, Q15858, Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Voltage-gated calcium and sodium channels, Generic PDBTM",1,8F0P,wildtype,Q15858,UniProt,C27 H35 F N4 O3 S2,546.72,X7L,"N-[6-(cyclopentylmethoxy)-1,3-benzothiazol-2-yl]-4-{[(1S,2S)-2-(dimethylamino)cyclohexyl]amino}-2-fluorobenzene-1-sulfonamide",CN(C)C1CCCCC1Nc2ccc(c(c2)F)S(=O)(=O)Nc3nc4ccc(cc4s3)OCC5CCCC5,6
8F0Q,,,,,,8F0Q,Cryo-EM reveals an unprecedented binding site for Na V 1.7 inhibitors enabling rational design of potent hybrid inhibitors.,Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the acylsulfonamide inhibitor GDC-0310,MEMBRANE PROTEIN/INHIBITOR,SCN9A,,"GO:0030424, GO:0001518, GO:0031402, GO:0005244, GO:0005248, GO:0061368, GO:0006954, GO:0086010, GO:0045759, GO:0019228, GO:0009791, GO:0034765, GO:0009409, GO:0009408, GO:0009636, GO:0019233, GO:0035725, GO:0006814, IPR005821, IPR000048, IPR001696, IPR044564, IPR010526, IPR024583, IPR028803, IPR043203, IPR027359, IPR031649, Q15858, Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Voltage-gated calcium and sodium channels, Generic PDBTM",1,8F0Q,wildtype,D0E0C2,UniProt,C25 H29 Cl2 F N2 O4 S,543.478,X7R,"5-cyclopropyl-4-({1-[(1S)-1-(3,5-dichlorophenyl)ethyl]piperidin-4-yl}methoxy)-2-fluoro-N-(methanesulfonyl)benzamide",CC(c1cc(cc(c1)Cl)Cl)N2CCC(CC2)COc3cc(c(cc3C4CC4)C(=O)NS(=O)(=O)C)F,5
8F0R,,,,,,8F0R,Cryo-EM reveals an unprecedented binding site for Na V 1.7 inhibitors enabling rational design of potent hybrid inhibitors.,Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the arylsulfonamide inhibitor GNE-3565,MEMBRANE PROTEIN/INHIBITOR,SCN9A,,"GO:0030424, GO:0001518, GO:0031402, GO:0005244, GO:0005248, GO:0061368, GO:0006954, GO:0086010, GO:0045759, GO:0019228, GO:0009791, GO:0034765, GO:0009409, GO:0009408, GO:0009636, GO:0019233, GO:0035725, GO:0006814, IPR005821, IPR000048, IPR001696, IPR044564, IPR010526, IPR024583, IPR028803, IPR043203, IPR027359, IPR031649, Q15858, Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Voltage-gated calcium and sodium channels, Generic PDBTM",1,8F0R,wildtype,D0E0C2,UniProt,C25 H26 Cl F4 N5 O2 S,572.018,X7W,"5-chloro-4-({(1S,2S,4S)-2-(dimethylamino)-4-[3-(trifluoromethyl)phenyl]cyclohexyl}amino)-2-fluoro-N-(pyrimidin-4-yl)benzene-1-sulfonamide",CN(C)C1CC(CCC1Nc2cc(c(cc2Cl)S(=O)(=O)Nc3ccncn3)F)c4cccc(c4)C(F)(F)F,4
8F0S,,,,,,8F0S,Cryo-EM reveals an unprecedented binding site for Na V 1.7 inhibitors enabling rational design of potent hybrid inhibitors.,Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the hybrid inhibitor GNE-9296,MEMBRANE PROTEIN/INHIBITOR,"SCN9A, NENA",,"GO:0030424, GO:0001518, GO:0031402, GO:0005244, GO:0005248, GO:0061368, GO:0006954, GO:0086010, GO:0045759, GO:0019228, GO:0009791, GO:0034765, GO:0009409, GO:0009408, GO:0009636, GO:0019233, GO:0035725, GO:0006814, IPR005821, IPR000048, IPR001696, IPR044564, IPR010526, IPR024583, IPR028803, IPR043203, IPR027359, IPR031649, Q15858, Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Voltage-gated calcium and sodium channels, Generic PDBTM",1,8F0S,wildtype,Q15858,UniProt,C27 H34 Cl F2 N3 O4 S,570.091,X80,"5-chloro-4-(cyclopentylmethoxy)-N-(4-{[(1S,2S)-2-(dimethylamino)cyclohexyl]amino}-2-fluorobenzene-1-sulfonyl)-2-fluorobenzamide",CN(C)C1CCCCC1Nc2ccc(c(c2)F)S(=O)(=O)NC(=O)c3cc(c(cc3F)OCC4CCCC4)Cl,6
8G5Y,,,,,,8G5Y,mRNA decoding in human is kinetically and structurally distinct from bacteria.,mRNA decoding in human is kinetically and structurally distinct from bacteria (IC state),RIBOSOME,"RPS4X, CCG2, RPS4, SCAR",,"GO:0036464, GO:0005829, GO:0022626, GO:0022627, GO:0070062, GO:0005925, GO:0016020, GO:0005654, GO:0005844, GO:1990904, GO:0005840, GO:0015935, GO:0003723, GO:0019843, GO:0003735, GO:0002181, GO:0008284, GO:0045727, GO:0045471, GO:0006412, IPR032277, IPR005824, IPR041982, IPR014722, IPR000876, IPR013845, IPR038237, IPR013843, IPR018199, IPR002942, IPR036986, P62701",9,8G5Y,wildtype,P62701,UniProt,C26 H35 N O6,457.559,3H3,"4-{(2R,5S,6E)-2-hydroxy-5-methyl-7-[(2R,3S,4E,6Z,10E)-3-methyl-12-oxooxacyclododeca-4,6,10-trien-2-yl]-4-oxooct-6-en-1-yl}piperidine-2,6-dione",CC1C=CC=CCCC=CC(=O)OC1C(=CC(C)C(=O)CC(CC2CC(=O)NC(=O)C2)O)C,89
8G5Z,,,,,,8G5Z,mRNA decoding in human is kinetically and structurally distinct from bacteria.,mRNA decoding in human is kinetically and structurally distinct from bacteria (GA state),RIBOSOME,,,,3,8G5Z,wildtype,555853,GenBank,C14 H19 N O4,265.305,ANM,ANISOMYCIN,CC(=O)OC1C(CNC1Cc2ccc(cc2)OC)O,91
8G5Z,,,,,,8G5Z,mRNA decoding in human is kinetically and structurally distinct from bacteria.,mRNA decoding in human is kinetically and structurally distinct from bacteria (GA state),RIBOSOME,"RPS3A, FTE1, MFTL",,"GO:0005737, GO:0005829, GO:0022626, GO:0022627, GO:0005783, GO:0070062, GO:0005925, GO:0005730, GO:0005654, GO:0005634, GO:1990904, GO:0045202, GO:0048027, GO:0003723, GO:0003735, GO:0030154, GO:0002181, GO:0043066, GO:0006412, GO:0006413, IPR027500, IPR001593, IPR018281, P61247",5,8G5Z,wildtype,P61247,UniProt,C26 H35 N O6,457.559,3H3,"4-{(2R,5S,6E)-2-hydroxy-5-methyl-7-[(2R,3S,4E,6Z,10E)-3-methyl-12-oxooxacyclododeca-4,6,10-trien-2-yl]-4-oxooct-6-en-1-yl}piperidine-2,6-dione",CC1C=CC=CCCC=CC(=O)OC1C(=CC(C)C(=O)CC(CC2CC(=O)NC(=O)C2)O)C,93
8G5Z,,,,,,8G5Z,mRNA decoding in human is kinetically and structurally distinct from bacteria.,mRNA decoding in human is kinetically and structurally distinct from bacteria (GA state),RIBOSOME,"RPS2, RPS4",,"GO:0005737, GO:0005829, GO:0022626, GO:0022627, GO:0070062, GO:0005925, GO:0016020, GO:0005654, GO:0005634, GO:0045296, GO:0019899, GO:0017134, GO:0003729, GO:0003723, GO:0003735, GO:0002181, GO:0051443, GO:0006412, IPR000851, IPR005324, IPR020568, IPR014721, IPR005711, IPR013810, IPR018192, P15880",10,8G5Z,wildtype,P15880,UniProt,C57 H87 N7 O15,1110.339,ZIY,plitidepsin,CCC(C)C1C(CC(=O)OC(C(=O)C(C(=O)NC(C(=O)N2CCCC2C(=O)N(C(C(=O)OC(C(C(=O)N1)NC(=O)C(CC(C)C)N(C)C(=O)C3CCCN3C(=O)C(=O)C)C)Cc4ccc(cc4)OC)C)CC(C)C)C)C(C)C)O,98
8G60,,,,,,8G60,mRNA decoding in human is kinetically and structurally distinct from bacteria.,mRNA decoding in human is kinetically and structurally distinct from bacteria (CR state),RIBOSOME,RPS29,,"GO:0005737, GO:0098556, GO:0005829, GO:0022627, GO:0070062, GO:0005925, GO:0005654, GO:0042788, GO:0015935, GO:0003735, GO:0008270, GO:0002181, GO:0006412, IPR039744, IPR001209, IPR043140, IPR018271, P62273",23,8G60,wildtype,P62273,UniProt,C57 H87 N7 O15,1110.339,ZIY,plitidepsin,CCC(C)C1C(CC(=O)OC(C(=O)C(C(=O)NC(C(=O)N2CCCC2C(=O)N(C(C(=O)OC(C(C(=O)N1)NC(=O)C(CC(C)C)N(C)C(=O)C3CCCN3C(=O)C(=O)C)C)Cc4ccc(cc4)OC)C)CC(C)C)C)C(C)C)O,97
8G61,,,,,,8G61,mRNA decoding in human is kinetically and structurally distinct from bacteria.,mRNA decoding in human is kinetically and structurally distinct from bacteria (AC state),RIBOSOME,RPS9,,"GO:0005737, GO:0005829, GO:0022626, GO:0022627, GO:0070062, GO:0005925, GO:0016020, GO:0005730, GO:0005654, GO:0005634, GO:1990904, GO:0005840, GO:0015935, GO:0045202, GO:0003723, GO:0019843, GO:0003735, GO:0045182, GO:0002181, GO:0008284, GO:0045903, GO:0006412, IPR022801, IPR005710, IPR001912, IPR018079, IPR002942, IPR036986, P46781",8,8G61,wildtype,P46781,UniProt,C14 H19 N O4,265.305,ANM,ANISOMYCIN,CC(=O)OC1C(CNC1Cc2ccc(cc2)OC)O,88
8G61,,,,,,8G61,mRNA decoding in human is kinetically and structurally distinct from bacteria.,mRNA decoding in human is kinetically and structurally distinct from bacteria (AC state),RIBOSOME,RPS5,,"GO:0005737, GO:0005829, GO:0022626, GO:0022627, GO:0070062, GO:0005925, GO:0016020, GO:0005654, GO:1990904, GO:0005840, GO:0003729, GO:0003723, GO:0019843, GO:0003735, GO:0002181, GO:0006450, GO:0000028, GO:0006412, GO:0006413, IPR000235, IPR005716, IPR020606, IPR023798, IPR036823, P46782",12,8G61,wildtype,P46782,UniProt,C26 H35 N O6,457.559,3H3,"4-{(2R,5S,6E)-2-hydroxy-5-methyl-7-[(2R,3S,4E,6Z,10E)-3-methyl-12-oxooxacyclododeca-4,6,10-trien-2-yl]-4-oxooct-6-en-1-yl}piperidine-2,6-dione",CC1C=CC=CCCC=CC(=O)OC1C(=CC(C)C(=O)CC(CC2CC(=O)NC(=O)C2)O)C,90
8G6J,,,,,,8G6J,mRNA decoding in human is kinetically and structurally distinct from bacteria.,mRNA decoding in human is kinetically and structurally distinct from bacteria (GA state 2),RIBOSOME,"RPS6, OK/SW-cl.2",,"GO:0044297, GO:0005737, GO:0036464, GO:0005829, GO:0022626, GO:0022627, GO:0030425, GO:0005783, GO:0016020, GO:0005730, GO:0005654, GO:0005634, GO:0048471, GO:0005844, GO:1990904, GO:0015935, GO:0019901, GO:0003723, GO:0003735, GO:0006924, GO:0002181, GO:0048821, GO:0000082, GO:0007369, GO:0042593, GO:0022605, GO:0043066, GO:0001890, GO:0043065, GO:0008284, GO:0042274, GO:0006364, GO:0033077, GO:0002309, GO:0031929, GO:0006412, IPR014401, IPR001377, IPR018282, P62753",11,8G6J,wildtype,P62753,UniProt,C40 H71 N7 O9,794.033,YRB,"(3R,6R,9S,12S,15S,18S,20R,24aR)-6-[(2S)-butan-2-yl]-3,12-bis[(1R)-1-hydroxy-2-methylpropyl]-8,9,11,17,18-pentamethyl-15-[(2S)-2-methylbutyl]hexadecahydropyrido[1,2-a][1,4,7,10,13,16,19]heptaazacyclohenicosine-1,4,7,10,13,16,19(21H)-heptone",CCC(C)CC1C(=O)N(C(C(=O)N2CCCCC2C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)C)O)C)C)C)C(C)CC)C(C(C)C)O)C)C,97
8GAE,,,,,,8GAE,Hsp90 provides a platform for kinase dephosphorylation by PP5.,Hsp90 provides platform for CRaf dephosphorylation by PP5,CHAPERONE,"CDC37, CDC37A",,"GO:0101031, GO:0005737, GO:0005829, GO:0070062, GO:1990565, GO:0051087, GO:0031072, GO:0051879, GO:0019900, GO:0019901, GO:0019887, GO:0097110, GO:0051082, GO:0098779, GO:0010608, GO:0006457, GO:0050821, GO:0006605, GO:0000079, GO:0060334, GO:0060338, IPR004918, IPR013873, IPR013874, IPR038189, IPR013855, Q16543",2,8GAE,Mutant,Q16543,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,7
8GLP,,,,,,8GLP,mRNA decoding in human is kinetically and structurally distinct from bacteria.,mRNA decoding in human is kinetically and structurally distinct from bacteria (Consensus LSU focused refined structure),RIBOSOME,"RPS6, OK/SW-cl.2",,"GO:0044297, GO:0005737, GO:0036464, GO:0005829, GO:0022626, GO:0022627, GO:0030425, GO:0005783, GO:0016020, GO:0005730, GO:0005654, GO:0005634, GO:0048471, GO:0005844, GO:1990904, GO:0015935, GO:0019901, GO:0003723, GO:0003735, GO:0006924, GO:0002181, GO:0048821, GO:0000082, GO:0007369, GO:0042593, GO:0022605, GO:0043066, GO:0001890, GO:0043065, GO:0008284, GO:0042274, GO:0006364, GO:0033077, GO:0002309, GO:0031929, GO:0006412, IPR014401, IPR001377, IPR018282, P62753",11,8GLP,wildtype,P62753,UniProt,C26 H35 N O6,457.559,3H3,"4-{(2R,5S,6E)-2-hydroxy-5-methyl-7-[(2R,3S,4E,6Z,10E)-3-methyl-12-oxooxacyclododeca-4,6,10-trien-2-yl]-4-oxooct-6-en-1-yl}piperidine-2,6-dione",CC1C=CC=CCCC=CC(=O)OC1C(=CC(C)C(=O)CC(CC2CC(=O)NC(=O)C2)O)C,87
8GV8,,,,,,8GV8,"The structural basis of the pH-homeostasis mediated by the Cl - /HCO 3 - exchanger, AE2.",The cryo-EM structure of hAE2 with DIDS,TRANSPORT PROTEIN,"SLC4A2, AE2, EPB3L1, HKB3, MPB3L",,"GO:0016324, GO:0016323, GO:0005925, GO:0016020, GO:0005886, GO:0008509, GO:0140900, GO:0019899, GO:0005452, GO:0022857, GO:0097186, GO:0006820, GO:0015701, GO:0048565, GO:0050801, GO:0043377, GO:2000565, GO:0030316, GO:0070175, GO:0032956, GO:0045124, GO:0051453, GO:0007283, GO:0055085, IPR001717, IPR002978, IPR018241, IPR013769, IPR011531, IPR003020, IPR016152, P04920, Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Anion exchanger family, Generic PDBTM",1,8GV8,wildtype,P04920,UniProt,C16 H20 N2 O6 S4,464.6,4KU,"2,2'-ethane-1,2-diylbis{5-[(sulfanylmethyl)amino]benzenesulfonic acid}",c1cc(c(cc1NCS)S(=O)(=O)O)CCc2ccc(cc2S(=O)(=O)O)NCS,2
8HBF,,,,,,8HBF,NO binds to the distal site of haem in the fully activated soluble guanylate cyclase.,Structure of human soluble guanylate cyclase in the NO+Rio state at 3.1 angstrom,SIGNALING PROTEIN,"GUCY1B1, GUC1B3, GUCSB3, GUCY1B3",4.6.1.2,"GO:0098978, GO:0008074, GO:0098831, GO:0004016, GO:0047805, GO:0005525, GO:0004383, GO:0020037, GO:0051879, GO:0046872, GO:0044877, GO:0038023, GO:0008015, GO:0071732, GO:0006182, GO:0019934, GO:0007263, GO:0038060, GO:0070482, GO:0099555, IPR001054, IPR018297, IPR038158, IPR011644, IPR011645, IPR042463, IPR024096, IPR029787, Q02153",2,8HBF,Mutant,Q02153,UniProt,C20 H19 F N8 O2,422.416,GZO,"methyl ~{N}-[4,6-bis(azanyl)-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]-~{N}-methyl-carbamate",CN(c1c(nc(nc1N)c2c3cccnc3n(n2)Cc4ccccc4F)N)C(=O)OC,6
8IBU,,,,,,8IBU,Structural basis for motilin and erythromycin recognition by motilin receptor.,Cryo-EM structure of the erythromycin-bound motilin receptor-Gq protein complex,SIGNALING PROTEIN,,,,1,8IBU,wildtype,,,C37 H67 N O13,733.927,ERY,ERYTHROMYCIN A,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,6
8IF3,,,,,,8IF3,"Recognition Mechanism of a Novel Gabapentinoid Drug, Mirogabalin, for Recombinant Human alpha 2 delta 1, a Voltage-Gated Calcium Channel Subunit.",Structure of human alpha-2/delta-1 with mirogabalin,MEMBRANE PROTEIN,"CACNA2D1, CACNL2A, CCHL2A, MHS3",,"GO:0070062, GO:1990454, GO:0016529, GO:0005891, GO:0046872, GO:0005245, GO:0098703, GO:0070588, GO:0061577, GO:0006816, GO:0060402, GO:0086002, GO:1904646, GO:0086048, GO:1901843, GO:0045933, GO:1902514, GO:0051924, GO:0086091, GO:0098903, GO:0060307, IPR013680, IPR013608, IPR002035, IPR036465, P54289, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Channels: Calcium Ion-Selective.Ca<sub>v</sub> voltage-gated calcium channel 慣<sub>2</sub>灌1 subunit alone",1,8IF3,wildtype,P54289,UniProt,C12 H19 N O2,209.285,8X9,"2-[(1R,5S,6S)-6-(aminomethyl)-3-ethyl-6-bicyclo[3.2.0]hept-3-enyl]acetic acid",CCC1=CC2C(C1)CC2(CC(=O)O)CN,4
8IOY,,,,,,8IOY,Structures of the human Wilson disease copper transporter ATP7B.,Structure of ATP7B C983S/C985S/D1027A mutant with AMP-PNP,TRANSLOCASE,"ATP7B, PWD, WC1, WND",7.2.2.8,"GO:0005794, GO:0000139, GO:0005770, GO:0016020, GO:0005739, GO:0005886, GO:0032588, GO:0005524, GO:0016887, GO:0005507, GO:0005375, GO:0043682, GO:0140581, GO:0006878, GO:0006882, GO:0060003, GO:0055070, GO:0015677, GO:0006825, GO:0051649, GO:0034220, GO:0007595, GO:0015680, GO:0046688, GO:0051208, GO:1990961, IPR023299, IPR018303, IPR023298, IPR008250, IPR036412, IPR023214, IPR017969, IPR006122, IPR006121, IPR036163, IPR027256, IPR001757, IPR044492, P35670, Transmembrane.Alpha-helical polytopic.P-type ATPase (P-ATPase).Copper-transporting P-type ATPase, Generic PDBTM",1,8IOY,Mutant,P35670,UniProt,C10 H17 N6 O12 P3,506.196,ANP,PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(NP(=O)(O)O)O)O)O)N,2
8SAQ,,,,,,8SAQ,Structural basis for breadth development in the HIV-1 V3-glycan targeting DH270 antibody clonal lineage.,CryoEM structure of DH270.6-CH848.0526.25,VIRAL PROTEIN/IMMUNE SYSTEM,,,"GO:0044175, GO:0020002, GO:0005886, GO:0019031, GO:0055036, GO:0005198, GO:0075512, GO:0039654, GO:0019064, GO:0019049, GO:1903905, GO:1903908, GO:1903911, GO:0019082, GO:0019062, IPR036377, IPR037527, IPR000328, IPR000777",1,8SAQ,wildtype,A0A1W6IHA4,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,7
8SAR,,,,,,8SAR,Structural basis for breadth development in the HIV-1 V3-glycan targeting DH270 antibody clonal lineage.,CryoEM structure of DH270.6-CH848.10.17,VIRAL PROTEIN/IMMUNE SYSTEM,,,"GO:0044175, GO:0020002, GO:0005886, GO:0019031, GO:0055036, GO:0005198, GO:0075512, GO:0039654, GO:0019064, GO:1903905, GO:1903908, GO:1903911, GO:0019082, GO:0019062, IPR036377, IPR037527, IPR000328, IPR000777",1,8SAR,wildtype,A0A1W6IPB2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,10
8SAV,,,,,,8SAV,Structural basis for breadth development in the HIV-1 V3-glycan targeting DH270 antibody clonal lineage.,CryoEM structure of VRC01-CH848.0526.25,VIRAL PROTEIN/IMMUNE SYSTEM,,,"GO:0044175, GO:0020002, GO:0005886, GO:0019031, GO:0055036, GO:0005198, GO:0075512, GO:0039654, GO:0019064, GO:0019049, GO:1903905, GO:1903908, GO:1903911, GO:0019082, GO:0019062, IPR036377, IPR037527, IPR000328, IPR000777",1,8SAV,wildtype,A0A1W6IHA4,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,8
